Thyroid Hormone Receptor-β Analogs for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

The most advanced compound, resmetirom, is an oral drug that demonstrated, in a large Phase III trial in MASH patients, the ability to remove liver fat, reduce aminotransferase levels and improve atherogenic dyslipidemia with a good tolerability profile.